For the quarter ending 2026-03-31, TARS made $162,054K in revenue. -$7,646K in net income. Net profit margin of -4.72%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 162,054 | 151,668 | 118,697 | 102,660 |
| Cost of sales-Product | - | 5,757* | - | - |
| Research and development | - | 18,283* | - | - |
| Selling, general and administrative | - | 135,605* | - | - |
| Total operating expenses | 168,176 | 159,644 | 133,226 | 124,844 |
| Loss from operations before other income (expense) | -6,122 | -7,976 | -14,529 | -22,184 |
| Interest income | 3,722 | 3,950 | 4,114 | 4,229 |
| Interest expense | 2,128 | 2,214 | 2,268 | 2,240 |
| Loss on debt extinguishment | - | 0 | 0 | 0 |
| Other income (expense), net | -87 | -74 | 98 | -145 |
| Total other income (expense), net | 1,507 | 1,662 | 1,944 | 1,844 |
| Loss before income taxes | - | -7,858* | - | - |
| Provision for income taxes | 2,352 | 515* | - | - |
| Net loss | -6,967 | -8,373 | -12,585 | -20,340 |
| Unrealized gain (loss) on marketable securities and cash equivalents | -679 | 92 | 250 | -46 |
| Comprehensive loss | -7,646 | -8,281 | -12,335 | -20,386 |
| Basic EPS | -0.16 | -0.193 | -0.3 | -0.48 |
| Diluted EPS | -0.16 | -0.193 | -0.3 | -0.48 |
| Basic Average Shares | 42,956,973 | 42,822,528 | 42,607,717 | 42,360,452 |
| Diluted Average Shares | 42,956,973 | 42,822,528 | 42,607,717 | 42,360,452 |
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)